- Home
- VANI vs BMEA Comparison
VANI vs BMEA Comparison
Compare VANI & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VANI
- BMEA
- Stock Information
- Founded
- VANI 1998
- BMEA 2017
- Country
- VANI United States
- BMEA United States
- Employees
- VANI N/A
- BMEA N/A
- Industry
- VANI Biotechnology: Electromedical & Electrotherapeutic Apparatus
- BMEA Biotechnology: Pharmaceutical Preparations
- Sector
- VANI Health Care
- BMEA Health Care
- Exchange
- VANI Nasdaq
- BMEA Nasdaq
- Market Cap
- VANI 68.1M
- BMEA 65.8M
- IPO Year
- VANI 2014
- BMEA 2021
- Fundamental
- Price
- VANI $1.26
- BMEA $1.44
- Analyst Decision
- VANI Strong Buy
- BMEA Strong Buy
- Analyst Count
- VANI 1
- BMEA 11
- Target Price
- VANI $4.00
- BMEA $27.60
- AVG Volume (30 Days)
- VANI 66.4K
- BMEA 703.1K
- Earning Date
- VANI 05-13-2025
- BMEA 05-05-2025
- Dividend Yield
- VANI N/A
- BMEA N/A
- EPS Growth
- VANI N/A
- BMEA N/A
- EPS
- VANI N/A
- BMEA N/A
- Revenue
- VANI N/A
- BMEA N/A
- Revenue This Year
- VANI N/A
- BMEA N/A
- Revenue Next Year
- VANI N/A
- BMEA N/A
- P/E Ratio
- VANI N/A
- BMEA N/A
- Revenue Growth
- VANI N/A
- BMEA N/A
- 52 Week Low
- VANI $0.91
- BMEA $1.29
- 52 Week High
- VANI $2.09
- BMEA $13.07
- Technical
- Relative Strength Index (RSI)
- VANI 77.37
- BMEA 39.69
- Support Level
- VANI $1.13
- BMEA $1.29
- Resistance Level
- VANI $1.16
- BMEA $1.52
- Average True Range (ATR)
- VANI 0.05
- BMEA 0.14
- MACD
- VANI 0.02
- BMEA 0.01
- Stochastic Oscillator
- VANI 92.86
- BMEA 28.17
About VANI Vivani Medical Inc. (DE)
Vivani Medical Inc is a preclinical-stage biopharmaceutical company. The company develops miniaturized, subdermal implants utilizing its proprietary NanoPortal technology to enable long-term, near-constant-rate delivery of a broad range of medicines to treat chronic diseases. It has two reporting segments, the Biopharm Division and the Neuromodulation Division. The Biopharm Division includes activities from NPM and Vivani Medical Australia Pty Ltd, and the Neurostimulation Division includes activities from Cortigent and its subsidiary in Switzerland.
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.